Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: A method includes obtaining behavioral source code defining logic to be performed using at least one logic device and constraints identifying data movements associated with execution of the logic. The at least one logic device contains multiple components that support at least one of: internal data movements within the at least one logic device and external data movements external to the logic device as defined by the behavioral source code and the constraints. The constraints identify characteristics of at least one of: the internal data movements and the external data movements. The method also includes automatically designing one or more data movers for use within the at least one logic device, where the one or more data movers are configured to perform at least one of the internal and external data movements in accordance with the characteristics.

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: Systems/techniques that facilitate deep learning multi-planar reformatting of medical images are provided. In various embodiments, a system can access a three-dimensional medical image. In various aspects, the system can localize, via execution of a machine learning model, a set of landmarks depicted in the three-dimensional medical image, a set of principal anatomical planes depicted in the three-dimensional medical image, and a set of organs depicted in the three-dimensional medical image. In various instances, the system can determine an anatomical orientation exhibited by the three-dimensional medical image, based on the set of landmarks, the set of principal anatomical planes, or the set of organs. In various cases, the system can rotate the three-dimensional medical image, such that the anatomical orientation now matches a predetermined anatomical orientation.

Abstract: Techniques are described for domain adaptation of image processing models using post-processing model correction According to an embodiment, a method comprises training, by a system operatively coupled to a processor, a post-processing model to correct an image-based inference output of a source image processing model that results from application of the source image processing model to a target image from a target domain that differs from a source domain, wherein the source image processing model was trained on source images from the source domain. In one or more implementations, the source imaging processing model comprises an organ segmentation model and the post-processing model can comprise a shape-autoencoder. The method further comprises applying, by the system, the source image processing model and the post-processing model to target images from the target domain to generate optimized image-based inference outputs for the target images.

Abstract: Systems/techniques that facilitate learning-based domain transformation for medical images are provided. In various embodiments, a system can access a medical image. In various aspects, the medical image can depict an anatomical structure according to a first medical scanning domain. In various instances, the system can generate, via execution of a machine learning model, a predicted image based on the medical image. In various aspects, the predicted image can depict the anatomical structure according to a second medical scanning domain that is different from the first medical scanning domain. In some cases, the first and second medical scanning domains can be first and second energy levels of a computed tomography (CT) scanning modality. In other cases, the first and second medical scanning domains can be first and second contrast phases of the CT scanning modality.

Abstract: Techniques are described for automatically detecting scan characteristics of a medical image series. According to an embodiment, a system is provided that comprises a memory that stores computer executable components, and a processor that executes the computer executable components stored in the memory. The computer executable components comprise an image generation component that generates a representative image of a medical image series comprising a plurality of scan images, and a series characterization component that processes the representative image using one or more characteristic detection algorithms to determine one or more characteristics of the medical image series. The system can further tailor the visualization layout for viewing the medical image series based on the one or more characteristics and/or automatically perform various workflow tasks based on the one or more characteristics.

Abstract: A system and method for estimating vascular flow using CT imaging include a computer readable storage medium having stored thereon a computer program comprising instructions, which, when executed by a computer, cause the computer to acquire a first set of data comprising anatomical information of an imaging subject, the anatomical information comprises information of at least one vessel. The instructions further cause the computer to process the anatomical information to generate an image volume comprising the at least one vessel, generate hemodynamic information based on the image volume, and acquire a second set of data of the imaging subject. The computer is also caused to generate an image comprising the hemodynamic information in combination with a visualization based on the second set of data.

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: Provided herein are methods of treating cancer in a patient comprising administering a total daily dose of 240 mg sotorasib to the patient, wherein the cancer is a KRAS G12C mutated cancer. Also provided herein are methods of treating KRAS G12C mutated cancer in a patient comprising administering a total daily dose of 960 mg sotorasib to the patient, and reducing the total daily dose of sotorasib to 480 mg in a patient experiencing an adverse event to the 960 mg dose of sotorasib.

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: A method includes obtaining behavioral source code defining logic to be performed using at least one logic device, hardware information associated with the at least one logic device, and constraints identifying user requirements associated with the at least one logic device. The method also includes generating a design for the at least one logic device using the behavioral source code, the hardware information, and the constraints. The design enables the at least one logic device to execute the logic while satisfying the user requirements. The design is generated using a machine learning/artificial intelligence (ML/AI) algorithm that iteratively modifies potential designs to meet the user requirements.

Abstract: Techniques are described for domain adaptation of image processing models using post-processing model correction According to an embodiment, a method comprises training, by a system operatively coupled to a processor, a post-processing model to correct an image-based inference output of a source image processing model that results from application of the source image processing model to a target image from a target domain that differs from a source domain, wherein the source image processing model was trained on source images from the source domain. In one or more implementations, the source imaging processing model comprises an organ segmentation model and the post-processing model can comprise a shape-autoencoder. The method further comprises applying, by the system, the source image processing model and the post-processing model to target images from the target domain to generate optimized image-based inference outputs for the target images.

Abstract: Systems and techniques for generating and/or employing a computed tomography (CT) medical imaging fracture model are presented. In one example, a system employs a first convolutional neural network associated with vertebrae segmentation to generate learned vertebrae segmentation data regarding a spine anatomical region related to a CT image. The system also employs a second convolutional neural network associated with fracture segmentation to generate, based on the learned vertebrae segmentation data, learned fracture segmentation data regarding the spine anatomical region. Furthermore, the system detects presence or absence of a medical fracture condition in the CT image based on the learned vertebrae segmentation data and the learned fracture segmentation data.

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: A system and method for estimating vascular flow using CT imaging include a computer readable storage medium having stored thereon a computer program comprising instructions, which, when executed by a computer, cause the computer to acquire a first set of data comprising anatomical information of an imaging subject, the anatomical information comprises information of at least one vessel. The instructions further cause the computer to process the anatomical information to generate an image volume comprising the at least one vessel, generate hemodynamic information based on the image volume, and acquire a second set of data of the imaging subject. The computer is also caused to generate an image comprising the hemodynamic information in combination with a visualization based on the second set of data.

Abstract: A system and method for estimating vascular flow using CT imaging include a computer readable storage medium having stored thereon a computer program comprising instructions, which, when executed by a computer, cause the computer to acquire a first set of data comprising anatomical information of an imaging subject, the anatomical information comprises information of at least one vessel. The instructions further cause the computer to process the anatomical information to generate an image volume comprising the at least one vessel, generate hemodynamic information based on the image volume, and acquire a second set of data of the imaging subject. The computer is also caused to generate an image comprising the hemodynamic information in combination with a visualization based on the second set of data.

Abstract: The present invention features interferon-free therapies for treating Hepatitis C Virus (HCV) genotypes 1b, 2, 3 or 4. In one aspect, the therapies comprises administering Compound 1 (Paritaprevir), Ritonavir, and Compound 2 (Ombitasvir) to a subject infected with HCV genotype 1b or 4, wherein the therapies do not include the administration of any interferon, and the therapies last from 8 to 12 weeks. Preferably, the therapies do not include the administration of any ribavirin.